Profound Medical Corp. Common Stock (PROF) is a publicly traded Healthcare sector company. As of May 21, 2026, PROF trades at $7.04 with a market cap of $250.37M and a P/E ratio of 5.58. PROF moved +2.38% today. Year to date, PROF is -10.94%; over the trailing twelve months it is +38.12%. Its 52-week range spans $3.76 to $9.17. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces PROF's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Profound Medical Showcases TULSA-PRO at AUA Meeting and PSMA PET Integration: Profound Medical will highlight its TULSA Procedure in four oral presentations at the AUA Annual Meeting on May 16 and demo TULSA-PRO at booth #413. The company launched an initiative to integrate PSMA PET molecular imaging into TULSA-PRO treatment planning software to enhance ablation precision and patient monitoring.
| Metric | Value |
|---|---|
| Price | $7.04 |
| Market Cap | $250.37M |
| P/E Ratio | 5.58 |
| EPS | $1.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.17 |
| 52-Week Low | $3.76 |
| Volume | 3 |
| Avg Volume | 0 |
| Revenue (TTM) | $18.81M |
| Net Income | $-38.90M |
| Gross Margin | 71.08% |
2 analysts cover PROF: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.